Based on this, an intriguing possibility is that STING agonists could sensitize tumors to PD1/PD‐L1 blockade therapies by increasing PD‐L1 abundance on tumor cells, thereby improving the binding efficiency of PD‐1/PD‐L1 antibodies. The gene discussed is STING1; the disease is neoplasm.